Form 4: Ionis Pharma Grants Stock Options to EVP Patrick O'Neil

Ionis Pharmaceuticals granted 19,350 non-qualified stock options to EVP, CLO & General Counsel Patrick R. O'Neil with an exercise price of $79.67.

Summary

• Patrick R. O'Neil, EVP, CLO & General Counsel of Ionis Pharmaceuticals Inc. (IONS), was granted 19,350 non-qualified stock options.
• The transaction date for this grant was January 2, 2026.
• The exercise price for these stock options is $79.67 per share.
• The options were granted under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
• The vesting schedule dictates that 25% of the shares subject to the option will vest and become exercisable on January 2, 2027.
• Following the initial vesting, the remaining shares will vest and become exercisable in 36 equal monthly installments over the subsequent three years.
• The expiration date for these stock options is January 1, 2036.
• Following this transaction, Patrick R. O'Neil beneficially owns 19,350 derivative securities directly.

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is a routine compensation event, aligning management's interests with long-term shareholder value. It is generally viewed as a neutral to slightly positive event as it reinforces executive commitment.

Positives

• The grant of stock options aligns the executive's long-term financial interests with those of the shareholders, incentivizing performance and retention.
• This is a standard component of executive compensation, reflecting ongoing commitment to the company's leadership.

Future Outlook

This filing does not contain specific forward-looking statements or guidance regarding the company's financial performance or strategic direction, as it is a report on an insider's beneficial ownership change.

Industry Context

The grant of stock options to key executives is a common practice in the biotechnology and pharmaceutical industries, used to attract, retain, and motivate talent by linking their compensation to the company's long-term stock performance.

Comparison to Industry Standards

• The structure of this stock option grant, including the vesting schedule and expiration date, is consistent with typical executive equity compensation packages observed across the biotechnology and pharmaceutical sectors.
• Companies like Biogen, Gilead Sciences, and Amgen frequently utilize similar equity incentive plans to compensate their senior leadership, aligning executive interests with shareholder value creation.

Corporate Governance

Related Party Transactions

• The grant of stock options to Patrick R. O'Neil, an executive officer of Ionis Pharmaceuticals, constitutes a related party transaction as it involves the company and an insider.

Stakeholder Impact

• Shareholders: The grant aims to align the executive's interests with long-term shareholder value creation, potentially leading to improved company performance.
• Employees: May signal stability in executive leadership and a commitment to performance-based incentives within the company.

Next Steps

• The options will begin to vest on January 2, 2027, with subsequent monthly vesting over the following three years.
• Patrick R. O'Neil may choose to exercise these options at any time after they vest and before their expiration date of January 1, 2036.

Key Dates

Recommendation

This Form 4 reports a routine stock option grant to a key executive, which is a standard compensation practice. It does not provide new information that would significantly alter the investment thesis for Ionis Pharmaceuticals, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Ionis Pharmaceuticals, IONS, Stock Option, Executive Compensation, Insider Transaction, Form 4, Patrick O'Neil, Equity Incentive Plan